ClinicaliQ Trial Snapshot
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) — Recruiting • Phase I • Oncology • NCT06428409.
- Drug being tested: Sacituzumab tirumotecan (MK-2870), a targeted antibody-drug conjugate, is being evaluated as monotherapy or in combination with other treatments for advanced or unresectable gastrointestinal cancers.
- Patient eligibility overview: The trial enrolls patients with advanced (metastatic) or unresectable gastrointestinal cancers who have received limited or no prior treatment, with specific eligibility criteria determined by cancer type and treatment history.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surgery). The goals of this study are to learn: * About the safety of sacituzumab tirumotecan alone or with other treatments and if people tolerate it * How many people have the cancer respond (get smaller or go away) to treatment
Eligibility Snapshot
- : The main inclusion criteria include but are not limited to the following: * Has one of the following cancers: * Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer * Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer * Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer * Advanced and/or unresectable BTC and has not received prior therapy for the cancer * For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.